Portopulmonary Hypertension: An Updated Review

Portal hypertension may have major consequences on the pulmonary vasculature due to the complex pathophysiological interactions between the liver and lungs. Portopulmonary hypertension (PoPH), a subset of group 1 pulmonary hypertension (PH), is a serious pulmonary vascular disease secondary to portal hypertension, and is the fourth most common subtype of pulmonary arterial hypertension. It is most commonly observed in cirrhotic patients; however, patients with noncirrhotic portal hypertension can also develop it. On suspicion of PoPH, the initial evaluation is by a transthoracic echocardiogram in which, if elevated pulmonary pressures are shown, patients should undergo right heart catheterization to confirm the diagnosis. The prognosis is extremely poor in untreated patients; therefore, management includes pulmonary arterial hypertension therapies with the aim of improving pulmonary hemodynamics and moving patients to orthotopic liver transplantation (OLT). In this article, we review in detail the epidemiology, pathophysiology, process for diagnosis, and most current treatments including OLT and prognosis in patients with PoPH. In addition, we present a diagnostic algorithm that includes the current criteria to properly select patients with PoPH who are candidates for OLT.

Citing Articles

Addition of a Loop Diuretic to Norepinephrine During Treatment of Hepatorenal Syndrome Type 1.

Velez J, Wickman T, Tayebi K, Mohamed M, Yousuf A, Kanduri S Kidney Int Rep. 2025; 10(2):466-474.

PMID: 39990915 PMC: 11843126. DOI: 10.1016/j.ekir.2024.11.013.

Porto-Sinusoidal Vascular Disease and Downhill Varices: Separate Clinical Entities?.

Pestana I, Ferreira C, Luis R, Sousa R, Pereira E, Banhudo A GE Port J Gastroenterol. 2025; 32(1):54-60.

PMID: 39906509 PMC: 11790272. DOI: 10.1159/000539092.

Emergency ECMO Deployment During Liver Transplantation in Portopulmonary Hypertension Patients.

Da Costa Rodrigues J, Gazarian C, Maillard J, Albu G, Assouline B, Lador F Am J Case Rep. 2025; 26:e946268.

PMID: 39891381 PMC: 11791688. DOI: 10.12659/AJCR.946268.

Pulmonary hypertension post-liver transplant: A case report.

Alharbi S, Alturaif N, Mostafa Y, Alfhaid A, Albenmousa A, Alghamdi S World J Gastrointest Surg. 2024; 16(12):3875-3880.

PMID: 39734439 PMC: 11650223. DOI: 10.4240/wjgs.v16.i12.3875.

Association of mildly elevated pulmonary vascular resistance with major cardiovascular events in pulmonary hypertension and chronic kidney disease: A retrospective cohort analysis.

Martinez Manzano J, Prendergast A, John T, Leguizamon R, McLaren I, Khan R Pulm Circ. 2024; 14(2):e12401.

PMID: 38887741 PMC: 11181768. DOI: 10.1002/pul2.12401.

References

Thevenot T, Savale L, Sitbon O . Portopulmonary hypertension: An unfolding story. Clin Res Hepatol Gastroenterol. 2020; 45(1):101492. DOI: 10.1016/j.clinre.2020.06.017. View

Bolognesi M, Di Pascoli M, Verardo A, Gatta A . Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol. 2014; 20(10):2555-63. PMC: 3949264. DOI: 10.3748/wjg.v20.i10.2555. View

Cartin-Ceba R, Swanson K, Iyer V, Wiesner R, Krowka M . Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest. 2010; 139(1):109-14. DOI: 10.1378/chest.10-0574. View

Lee B, Vittinghoff E, Dodge J, Cullaro G, Terrault N . National Trends and Long-term Outcomes of Liver Transplant for Alcohol-Associated Liver Disease in the United States. JAMA Intern Med. 2019; 179(3):340-348. PMC: 6439700. DOI: 10.1001/jamainternmed.2018.6536. View

Abuhalimeh B, Krowka M, Tonelli A . Treatment Barriers in Portopulmonary Hypertension. Hepatology. 2018; 69(1):431-443. PMC: 6460471. DOI: 10.1002/hep.30197. View

Rodriguez-Almendros N, Toapanta-Yanchapaxi L, Aguirre Valadez J, Espinola Zavaleta N, Munoz-Martinez S, Garcia-Juarez I . [Portopulmonary hypertension: Updated review]. Arch Cardiol Mex. 2016; 88(1):25-38. DOI: 10.1016/j.acmx.2016.11.002. View

Sendra C, Carballo-Rubio V, Sousa J . Hepatopulmonary Syndrome and Portopulmonary Hypertension: Management in Liver Transplantation in the Horizon 2020. Transplant Proc. 2020; 52(5):1503-1506. DOI: 10.1016/j.transproceed.2020.02.057. View

Burra P, Becchetti C, Germani G . NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Rep. 2020; 2(6):100192. PMC: 7607500. DOI: 10.1016/j.jhepr.2020.100192. View

De Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C . Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022; 76(4):959-974. PMC: 11090185. DOI: 10.1016/j.jhep.2021.12.022. View

10.

Aggarwal M, Li M, Bhardwaj A, Wallace W, Wang X, Carey W . Predictors of survival in portopulmonary hypertension: a 20-year experience. Eur J Gastroenterol Hepatol. 2021; 34(4):449-456. PMC: 8891035. DOI: 10.1097/MEG.0000000000002322. View

11.

Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues S . Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. Am J Gastroenterol. 2021; 116(4):723-732. DOI: 10.14309/ajg.0000000000000994. View

12.

Salgia R, Goodrich N, Simpson H, Merion R, Sharma P . Outcomes of liver transplantation for porto-pulmonary hypertension in model for end-stage liver disease era. Dig Dis Sci. 2014; 59(8):1976-82. PMC: 4119507. DOI: 10.1007/s10620-014-3065-y. View

13.

Zardi E, Zardi D, Giorgi C, Chin D, Dobrina A . Portopulmonary hypertension and hepatorenal syndrome. Two faces of the same coin. Eur J Intern Med. 2017; 43:22-27. DOI: 10.1016/j.ejim.2017.05.028. View

14.

Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S . Portopulmonary hypertension in the current era of pulmonary hypertension management. J Hepatol. 2020; 73(1):130-139. DOI: 10.1016/j.jhep.2020.02.021. View

15.

DuBrock H, Goldberg D, Sussman N, Bartolome S, Kadry Z, Salgia R . Predictors of Waitlist Mortality in Portopulmonary Hypertension. Transplantation. 2017; 101(7):1609-1615. PMC: 5481480. DOI: 10.1097/TP.0000000000001666. View

16.

Krowka M, Plevak D, Findlay J, Rosen C, Wiesner R, Krom R . Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl. 2000; 6(4):443-50. DOI: 10.1053/jlts.2000.6356. View

17.

Li J, Zhuang Q, Zhang X, Zheng Y, Qiao Z, Zhang J . Prevalence and Prognosis of Portopulmonary Hypertension in 223 Liver Transplant Recipients. Can Respir J. 2018; 2018:9629570. PMC: 6167565. DOI: 10.1155/2018/9629570. View

18.

Hodgson J, Swietlik E, Salmon R, Hadinnapola C, Nikolic I, Wharton J . Characterization of Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2019; 201(5):575-585. PMC: 7047445. DOI: 10.1164/rccm.201906-1141OC. View

19.

Simonneau G, Montani D, Celermajer D, Denton C, Gatzoulis M, Krowka M . Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2018; 53(1). PMC: 6351336. DOI: 10.1183/13993003.01913-2018. View

20.

Khaderi S, Khan R, Safdar Z, Stribling R, Vierling J, Goss J . Long-term follow-up of portopulmonary hypertension patients after liver transplantation. Liver Transpl. 2014; 20(6):724-7. DOI: 10.1002/lt.23870. View